Indication
Primary Sclerosing Cholangitis
24 clinical trials
23 products
1 drug
Product
PLN-74809Product
PlaceboClinical trial
A Randomized, Double-blind, Dose-ranging, Placebo-controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Primary Sclerosing Cholangitis (PSC) and Suspected Liver Fibrosis (INTEGRIS-PSC)Status: Completed, Estimated PCD: 2024-02-26
Product
CM-101Clinical trial
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Evaluating the Safety and Efficacy of CM-101 in Subjects With Primary Sclerosing Cholangitis (The SPRING Study)Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC).Status: Recruiting, Estimated PCD: 2024-12-16
Product
ElafibranorProduct
Anti-human CCL24Clinical trial
An Open Label, Phase 2 Study to Evaluate the Effect of A3907 on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults With Primary Sclerosing Cholangitis (PSC)Status: Recruiting, Estimated PCD: 2025-06-14
Product
RitivixibatClinical trial
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing CholangitisStatus: Recruiting, Estimated PCD: 2025-09-01
Product
VolixibatClinical trial
A Randomized, Open-label, Phase 2 Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)Status: Terminated, Estimated PCD: 2019-01-31
Product
DUR-928Product
AramcholClinical trial
A Proof of Concept, Prospective, Randomized, Placebo-controlled, Double-blind, Study to Evaluate the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Patients With Primary Sclerosing CholangitisStatus: Not yet recruiting, Estimated PCD: 2025-09-01
Product
CilofexorClinical trial
A Proof-of-Concept, Open-Label Study Evaluating the Safety and Tolerability of Cilofexor in Subjects With Primary Sclerosing Cholangitis (PSC) and Compensated CirrhosisStatus: Terminated, Estimated PCD: 2021-09-02
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects With Primary Sclerosing CholangitisStatus: Terminated, Estimated PCD: 2022-11-10
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel Group, 12 Weeks, Therapeutic Exploratory Phase 2 Clinical Study to Evaluate the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis (PSC)Status: Completed, Estimated PCD: 2023-06-23
Product
HK-660SClinical trial
A Double-Blind, Randomized, Placebo-Controlled, Phase I Study To Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Escalating Subcutaneous Doses of CM-101 in Healthy Male SubjectsStatus: Completed, Estimated PCD: 2019-05-05
Clinical trial
The Effect of Statin Therapy on Bile Acid Physiology and the Microbiome in Primary Sclerosing Cholangitis (PSC): a Multi-omics StudyStatus: Recruiting, Estimated PCD: 2025-05-31
Product
RosuvastatinClinical trial
P.R.O.G.R.E.S.S.: PSC Resource Of Genetic Risk, Environment and Synergy Studies.Status: Active (not recruiting), Estimated PCD: 2050-12-01
Product
Genetic AnalysisClinical trial
A Prospective, Randomized, Multi-centered, Placebo-controlled Clinical Trial of Oral Vanycomycin in Adults With Primary Sclerosing CholangitisStatus: Recruiting, Estimated PCD: 2026-10-30
Product
VancomycinClinical trial
Detoxification of the Liver in Primary Sclerosing CholangitisStatus: Recruiting, Estimated PCD: 2025-09-01
Product
BRS201Clinical trial
Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for Primary Sclerosing CholangitisStatus: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
A Randomized, Placebo-controlled Pilot Study of Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis (PSC)Status: Recruiting, Estimated PCD: 2024-09-01
Product
SulfasalazineClinical trial
A Study of Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis(HAAPS Study).Status: Recruiting, Estimated PCD: 2025-05-01
Product
HymecromoneClinical trial
Liver Cirrhosis Network (LCN) Rosuvastatin Efficacy and Safety for Cirrhosis in the United States (RESCU): A Double-Blind Randomized, Placebo-Controlled Phase 2 StudyStatus: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
A Prospective, Randomized, Placebo-controlled Clinical Trial of Oral Vancomycin in Adults and Young Adults (15-17 Years Old) Affected by Primary Sclerosing Cholangitis With or Without Inflammatory Bowel DiseaseStatus: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Phase II Study to Evaluate Safety, Tolerability and Efficacy, of CS0159 in Patients Subjects With Primary Sclerosing Cholangitis, Multicenter, Randomized, 12-week Double-blind, Placebo-controlled, and 40-week Open StudyStatus: Recruiting, Estimated PCD: 2024-12-01
Product
CS0159Drug
VarlilumabClinical trial
Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, and Coronavirus Disease 2019 With [18F]FP-R01-MG-F2 With PET/CTStatus: Recruiting, Estimated PCD: 2025-04-14
Product
[18F]FP-R01-MG-F2Clinical trial
FARGO: A Randomised, Phase IIa, Multi-centre, Placebo-controlled Trial of FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitisStatus: Recruiting, Estimated PCD: 2026-04-30
Product
Faecal Microbiota TransplantClinical trial
A 12-Month, Open-Label Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Siplizumab as Induction Therapy in Patients With Autoimmune Liver Diseases Undergoing Liver Transplantation (SET-SAIL)Status: Not yet recruiting, Estimated PCD: 2025-12-31
Product
Siplizumab